BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14734709)

  • 1. Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production.
    Yamaguchi N; Hiraoka S; Mukai T; Takeuchi N; Zhou XY; Ono S; Kogo M; Dunussi-Joannopoulos K; Ling V; Wolf S; Fujiwara H
    J Immunol; 2004 Feb; 172(3):1347-54. PubMed ID: 14734709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
    Hiraoka S; Takeuchi N; Bian Y; Nakahara H; Kogo M; Dunussi-Joannopoulos K; Wolf S; Ono S; Fujiwara H
    Int Immunol; 2005 Aug; 17(8):1071-9. PubMed ID: 16027141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulatory effects of B7-related protein-1 on cellular and humoral immune responses in mice.
    Guo J; Stolina M; Bready JV; Yin S; Horan T; Yoshinaga SK; Senaldi G
    J Immunol; 2001 May; 166(9):5578-84. PubMed ID: 11313397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.
    Poehlein CH; Hu HM; Yamada J; Assmann I; Alvord WG; Urba WJ; Fox BA
    J Immunol; 2003 Feb; 170(4):2004-13. PubMed ID: 12574370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
    Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
    J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help.
    Harding FA; Allison JP
    J Exp Med; 1993 Jun; 177(6):1791-6. PubMed ID: 7684435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile.
    Broeren CP; Gray GS; Carreno BM; June CH
    J Immunol; 2000 Dec; 165(12):6908-14. PubMed ID: 11120816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7 requirements for primary and secondary protein- and polysaccharide-specific Ig isotype responses to Streptococcus pneumoniae.
    Wu ZQ; Khan AQ; Shen Y; Schartman J; Peach R; Lees A; Mond JJ; Gause WC; Snapper CM
    J Immunol; 2000 Dec; 165(12):6840-8. PubMed ID: 11120807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL.
    Zuberek K; Ling V; Wu P; Ma HL; Leonard JP; Collins M; Dunussi-Joannopoulos K
    Cell Immunol; 2003 Sep; 225(1):53-63. PubMed ID: 14643304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection.
    Lumsden JM; Roberts JM; Harris NL; Peach RJ; Ronchese F
    J Immunol; 2000 Jan; 164(1):79-85. PubMed ID: 10604996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells.
    Hoshino T; Yagita H; Ortaldo JR; Wiltrout RH; Young HA
    Eur J Immunol; 2000 Jul; 30(7):1998-2006. PubMed ID: 10940889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
    Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
    J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.
    Sturmhoefel K; Lee K; Gray GS; Thomas J; Zollner R; O'Toole M; Swiniarski H; Dorner A; Wolf SF
    Cancer Res; 1999 Oct; 59(19):4964-72. PubMed ID: 10519410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
    Yang G; Hellström KE; Hellström I; Chen L
    J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.